FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anja Möricke

Research Profile

Disorders

Living Beings

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Petra Dörge; Jochen Harbott; Rolf Koehler; Wolf-Dieter Ludwig; Barbara Meissner; Anja Möricke; Richard Ratei; Denis Schewe; Martin Schrappe; André Schrauder; Martin Stanulla; Andrea Teigler-Schlegel; Martin Zimmermann; Claus R Bartram; Jean-Pierre Bouquin; Gunnar Cario
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dagmar Denk; Anja Möricke; Karin Nebral; Gertrud Pass; Andishe Attarbaschi; Jutta Bradtke; Sabine Strehl
PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia.
Melchior Lauten; Barbara Meissner; Anja Möricke; Charlotte Niemeyer; Felix Niggli; Edelgard Odenwald; Hansjörg Riehm; Andishe Attarbaschi; Rita Beier; Martin Stanulla; Martin Zimmermann; Martin Schrappe
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anja Möricke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Petra Dörge; Jochen Harbott; Rolf Koehler; Wolf-Dieter Ludwig; Barbara Meissner; Anja Möricke; Richard Ratei; Denis Schewe; Martin Schrappe; André Schrauder; Martin Stanulla; Andrea Teigler-Schlegel; Martin Zimmermann; Claus R Bartram; Jean-Pierre Bouquin; Gunnar Cario
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Haematologica 2013;98(3):428-32.
2012: Dagmar Denk; Anja Möricke; Karin Nebral; Gertrud Pass; Andishe Attarbaschi; Jutta Bradtke; Sabine Strehl
PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia.
Leukemia research 2012;36(8):e178-81.
2012: Melchior Lauten; Barbara Meissner; Anja Möricke; Charlotte Niemeyer; Felix Niggli; Edelgard Odenwald; Hansjörg Riehm; Andishe Attarbaschi; Rita Beier; Martin Stanulla; Martin Zimmermann; Martin Schrappe
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Haematologica 2012;97(7):1048-56.
2012: Lutz Zeidler; Martin Zimmermann; Andrea Teigler-Schlegel; Christoph Tschan; Karl Welte; Dorothee Bartels; Claus R Bartram; Gunnar Cario; Lilia Goudeva; Sarah Jäger; Rolf Koehler; Wolf-Dieter Ludwig; Barbara Meissner; Anja Möricke; Richard Ratei; Hansjörg Riehm; Martin Schrappe; André Schrauder; Julia Skokowa; Martin Stanulla
Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.
Haematologica 2012;97(3):402-9.
2011: Klaus Bienemann; Kirsten Bienemann; Birgit Burkhardt; Gabriele Escherich; Gritta E Janka-Schaub; Dieter Körholz; Christine Mauz-Körholz; Ulrike Meyer; Simon Modlich; Anja Möricke; Alfred Reiter; Martin Schrappe; Martin Zimmermann; Arndt Borkhardt
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
British journal of haematology 2011;155(4):468-76.
2011: Daniel Steinbach; Brigitte Strahm; Arend von Stackelberg; Bernhard Wilhelm; Martin Zimmermann; Ursula Creutzig; Klaus-Michael Debatin; Bernd Gruhn; Heribert Jürgens; Hans-Rudolf Kiermaier; Dirk Reinhardt; Martin Schrappe; Anja Möricke
Long term survival in children with acute leukaemia and complications requiring mechanical ventilation.
Archives of disease in childhood 2011;96(11):1026-32.
2011: Dominik Schrey; Katharina Speitel; Joachim Gerss; Claudia Lanvers-Kaminsky; Anja Möricke; Joachim Boos
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
Pediatric blood & cancer 2011;57(3):378-84.
2011: Martin Schrappe; André Schrauder; Maria Grazia Valsecchi; Jacques J M van Dongen; Karl Welte; Martin Zimmermann; Maurizio Aricò; Claus R Bartram; Giuseppe Basso; Andrea Biondi; Barbara Buldini; Giovanni Cazzaniga; Michael Dworzak; Helmut Gadner; Thomas Klingebiel; Rolf Koehler; Franco Locatelli; Chiara Messina; Anja Möricke; Renate Panzer-Grümayer; Rosanna Parasole; Richard Ratei; Alfred Reiter; Beat W Schäfer; Valentino Conter
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
Blood 2011;118(8):2077-84.
2011: Lüder Hinrich Meyer; Sarah Mirjam Eckhoff; Manon Queudeville; Johann Michael Kraus; Marco Giordan; Jana Stursberg; Andrea Zangrando; Elena Vendramini; Anja Möricke; Martin Zimmermann; Andre Schrauder; G Lahr; Karlheinz Holzmann; Martin Schrappe; Giuseppe Basso; Karsten Stahnke; Hans Armin Kestler; Geertruy Te Kronnie; Klaus-Michael Debatin
Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways.
Cancer cell 2011;19(2):206-17.
2010: Dominik Schrey; Stephan Borghorst; Claudia Lanvers-Kaminsky; Georg Hempel; Joachim Gerss; Anja Möricke; Martin Schrappe; Joachim Boos
Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Pediatric blood & cancer 2010;54(7):952-8.
2010: Herbert Pichler; Anja Möricke; Georg Mann; Andrea Teigler-Schlegel; Felix Niggli; Karin Nebral; Margit König; Andrea Inthal; Daniela Krehan; Michael Dworzak; Dasa Janousek; Jochen Harbott; Martin Schrappe; Helmut Gadner; Sabine Strehl; Oskar A Haas; Renate Panzer-Grümayer; Andishe Attarbaschi
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
British journal of haematology 2010;149(1):93-100.
2010: Anja Möricke; Martin Zimmermann; Alfred Reiter; Günter Henze; André Schrauder; Helmut Gadner; Wolf-Dieter Ludwig; J Ritter; Jochen Harbott; Georg Mann; Thomas Klingebiel; Felix Zintl; C Niemeyer; Bernhard Kremens; Felix Niggli; Dietrich Niethammer; Karl Welte; Martin Stanulla; E Odenwald; Hansjörg Riehm; Martin Schrappe
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Leukemia 2010;24(2):265-84.
2009: Marieke H van der Linden; Maria Grazia Valsecchi; Paola de Lorenzo; Anja Möricke; Gritta Janka; Thierry Leblanc; Maria Felice; Andrea Biondi; Myriam Campbell; Ian Hann; Jeffrey E Rubnitz; Jan Stary; Tomasz Szczepanski; Ajay Vora; Alina Ferster; Liisa Hovi; Lewis B Silverman; Rob Pieters
Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.
Blood 2009;114(18):3764-8.
2009: Arne Kristian Schwarz; Martin Stanulla; Gunnar Cario; Thomas Flohr; Rosemary Sutton; Anja Möricke; Philippe Anker; Maurice Stroun; Karl Welte; Claus R Bartram; Martin Schrappe; André Schrauder
Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia.
Annals of hematology 2009;88(9):897-905.
2009: Martin Stanulla; Elke Schaeffeler; Anja Möricke; Sally A Coulthard; Gunnar Cario; André Schrauder; Peter Kaatsch; Michael Dördelmann; Karl Welte; Martin Zimmermann; Alfred Reiter; Michel Eichelbaum; Hansjörg Riehm; Martin Schrappe; Matthias Schwab
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Blood 2009;114(7):1314-8.
2009: Ekaterini Kidas; Anja Möricke; Rita Beier; Karl Welte; Martin Schrappe; Martin Stanulla; Lorenz Grigull
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study.
International journal of hematology 2009;89(5):584-91.
2008: Gunnar Cario; Andrea Fetz; Christian Bretscher; Anja Möricke; André Schrauder; Martin Stanulla; Martin Schrappe
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia.
Annals of hematology 2008;87(9):709-16.
2008: Andishe Attarbaschi; Georg Mann; Renate Panzer-Grümayer; Silja Röttgers; Manuel Steiner; Margit König; Eva Csinady; Michael Dworzak; Markus Seidel; Dasa Janousek; Anja Möricke; Carsten Reichelt; Jochen Harbott; Martin Schrappe; Helmut Gadner; Oskar A Haas
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):3046-50.
2008: Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn D Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Blood 2008;111(9):4477-89.
2008: Anja Borgmann; Christina Zinn; Reinhard Hartmann; Ralf Herold; Peter Kaatsch; Gabriele Escherich; Anja Möricke; Günter Henze; Arend von Stackelberg
Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
European journal of cancer (Oxford, England : 1990) 2008;44(2):257-68.
2007: Gunnar Cario; Shai Izraeli; Anja Teichert; Peter Rhein; Julia Skokowa; Anja Möricke; Martin Zimmermann; André Schrauder; Leonid Karawajew; Wolf-Dieter Ludwig; Karl Welte; Holger J Schünemann; Brigitte Schlegelberger; Martin Schrappe; Martin Stanulla
High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4813-20.
2007: Martin Stanulla; Gunnar Cario; Barbara Meissner; André Schrauder; Anja Möricke; Hansjörg Riehm; Martin Schrappe
Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
Blood cells, molecules & diseases 2007;39(2):160-3.
2005: Anja Möricke; M Zimmermann; A Reiter; H Gadner; E Odenwald; Jochen Harbott; Wolf-Dieter Ludwig; Hansjörg Riehm; Martin Schrappe
Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Klinische Pädiatrie 2005;217(6):310-20.
2004: Barbara Meissner; Martin Stanulla; Wolf-Dieter Ludwig; Jochen Harbott; Anja Möricke; Karl Welte; Martin Schrappe
The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia.
Leukemia 2004;18(11):1920-3.